SynCell was selected for MassChallenge’s 2022 US Early-Stage Cohort

 

SynCell News • May 29, 2022

Yesterday, SynCell Biotechnology was selected to participate in the MassChallenge 2022 accelerator program. The company was one of over 1,000 other startup applications for this year’s program.

Accessing this incredible cohort and program will foster and promote the work we are trying to accomplish, as well as expose our technology to the great minds of potential partners and mentors” said our co-founder David Medina.

By participating in this accelerator, SynCell will receive unrivaled access to a global network of partners, experts, and mentors; residency options; market access opportunities; and more to bolster our efforts to solve the antimicrobial resistance crisis for zero cost and zero equity.

MassChallenge’s U.S. Early-Stage program is the global network for innovators. Headquartered in the United States with eight locations worldwide, it is the non-profit’s mission to help bold entrepreneurs disrupt the status quo and create sustainable change. Since launching in 2009, MassChallenge has run programs in 18 countries, supported more than 3,000 startups from around the world, and awarded over $17M in equity-free cash and prizes.